Private Healthcare in Portugal: Structure, Succession & Exit in Hospitals and Clinics

Portuguese private healthcare has been one of the most active M&A sectors of the past decade. The major domestic groups (Luz Saúde, CUF, Lusíadas, Trofa Saúde, HPA) and a continuous flow of international private capital investors have driven sustained consolidation across hospitals, polyclinics, imaging centres, MCDT laboratories, dental groups, ophthalmology platforms and fertility clinics. Underlying drivers — an ageing population, growing private insurance penetration via Multicare, Médis and Advancecare, and the structural pressure on the public NHS — make the medium-term thesis robust. The result: any independent operator with €5M+ in revenue can expect to be approached, repeatedly, over the next five years.

The defining structural problem in this sector is the inseparability of the founding clinician from the operation. In a typical Portuguese clinic or specialty hospital, the founder is simultaneously the lead physician, the clinical director, the largest revenue generator, the public face of the brand, and the de facto manager. Acquirers — strategic and financial alike — view this concentration as the single largest execution risk. Resolving it requires a multi-year transition: hiring a non-clinician CEO, formalising clinical governance through a medical board, redistributing patient relationships across associate physicians, and building exclusivity contracts with the medical staff that survive a change of ownership.

Corporate structure in private healthcare is almost always sub-optimal at the moment of first contact with an acquirer. The most common pattern: a single operating company holding the clinical licence, the medical equipment, the real estate and the founder's personal investments. This is wrong on multiple levels. The hospital real estate should be separated into a dedicated property vehicle — both to enable a future sale-leaseback (a standard structuring move that international healthcare investors actively seek) and to protect family wealth from clinical liability. The operating clinical entity should sit under a holding structured to capture the participation exemption regime on any future sale.

Regulatory and contractual assets are central to value. The ERS licence (Entidade Reguladora da Saúde), the conventions with public payers, and — most importantly — the agreements with private health insurers (Multicare, Médis, Advancecare and the corporate self-insured plans) are the contractual backbone of the business. In due diligence, acquirers will examine the renewal terms, the pricing grids, the volume commitments and any termination clauses in these agreements with forensic detail. Operators who maintain disciplined documentation, anticipate renewals 12-18 months in advance, and diversify across payers consistently command premium valuations.

Succession planning is uniquely complex in healthcare because clinical reputation does not transfer mechanically. Unlike industrial businesses where institutional processes can survive the founder, a clinic's brand often is the founder. Effective succession requires a deliberate decade-long programme: recruiting and developing successor physicians with comparable clinical credentials, transferring teaching and conference visibility to the next generation, restructuring the partnership model to retain key talent post-transaction, and using shareholder agreements with tag-along, drag-along and non-compete provisions to protect the equity story for any future buyer.

Our perspective: private healthcare offers one of the most attractive risk-return profiles in Portuguese mid-market M&A — for owners who arrive at the table prepared. The combination of structural demand, sophisticated buyer universe, real estate optionality and recurring revenue streams creates a foundation for premium outcomes. But those outcomes are only realised by operators who have separated the clinical entity from the property, professionalised governance, formalised payer relationships, and resolved founder dependency. The remaining founders — clinicians who reach negotiation as both the seller and the irreplaceable asset — consistently underperform the market by 30-50% on transaction value.